Wet AMD is a serious and debilitating sight-threatening condition that requires ongoing treatment to prevent worsening.
News
Spravato reduces depressive symptoms in 24 hours
Both studies showed clinically meaningful and statistically significant superiority of the drug.
PRAC to review Picato skin cancer data
The committee will now carry out a thorough review of all available data, including from ongoing studies.
NHS to review making statins available for pharmacists
If only 45% of people with a high risk of cardiovascular disease were identified and treated, 6,000 strokes and heart attacks could be avoided over the next ten years.
Novartis confirms long-term efficacy, safety of Aimovig
Back in April the SMC accepted the drug for use in patients with chronic migraine.
EQL accepted by NHS accelerator programme
Earlier this year, EQL launched its debut product ‘Phio’, a chatbot that thinks and acts like a physiotherapist.
NHS to roll out high street heart checks
Cardiovascular disease costs the NHS £7 billion a year.
Imfinzi shows survival benefit in aggressive lung cancer
The drug cut the risk of death by 27%.
Only 1 week left to enter into the 2019 Sales Awards!
There is now only 1 week left to secure a place in the 2019 Sales Awards, which will be closing for entry on Friday the 13th of September.
EU Marketing Authorisation granted for Lonsurf
The approval is a “landmark decision for patients across the European Union.”
LIVI partners with Boots
The NHS Long Term Plan states that all patients should have access to online and video consultations by 2021.
EU approval for Tecentriq-based NSCLC combo
The drug is a monoclonal antibody designed to bind with a protein called PD-L1.
Keytruda combo bags EU approval in RCC
The combo reduced the risk of death by 47% in a clinical trial.
Spending Round provides ‘much-needed’ NHS funding
The NHS will recieve a cash increase of £33.9 billion a year by 2023-24 compared to 2018-19 budgets.
AstraZeneca, Theragnostics sign PARPi development agreement
The licensing agreement enables the company’s “freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi”.
